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Introduction
Lymphocytes are critical elements that mediate antitumor 
immune responses. A decrease in the total lymphocyte count 
and lymphocyte infiltration in pathological specimens is 
associated with poor overall survival and progression-free 
survival [1-6]. Both CD8+ T-cells and natural killer cells are 
critical mediators of the antitumor response owing to their 
ability to produce interferon-γ and to directly kill the target 
cells [7,8]. Moreover, T lymphocytes contribute significant-
ly to the efficacy of anticancer immunotherapy, including 
immune checkpoint inhibitors [9].
Lymphocytes and their precursors are very sensitive to 
ionizing radiation [10]. The lethal doses required to reduce 
the surviving fraction of lymphocytes by 50% and 90% are 
2 Gy and 3 Gy, respectively [11]. Although radiotherapy can 
induce lymphopenia by damaging the bone marrow, local 
radiotherapy to non-marrow organs (e.g., the liver, brain, 
esophagus, rectum, and pancreas) can also cause systemic 
lymphopenia due to irradiation of the circulating blood dur-
ing the course of conventional fractionated radiotherapy 
[1-6]. Therefore, novel strategies are urgently needed to pre-
serve the total lymphocyte count during radiotherapy. Iden-
tifying factors associated with radiation-induced lymphope-
nia will be the first step in overcoming the rapid depletion of 
lymphocytes during radiotherapy. However, little is known 
about the physiological response to and predictors of radia-
tion-induced lymphopenia in patients with solid tumors.
Interleukin (IL)-7, IL-15, and IL-2 are cytokines that possess 
a common γ-chain, which are critical for regulating lympho-
cyte homeostasis [12]. Recently, IL-7 has received increasing 
attention because its recombinant form was safely adminis-
tered to cancer patients [13]. Moreover, the use of IL-7 for 
overcoming lymphopenia and enhancing the therapeutic 
effect in cancer patients is being actively explored in several 
clinical trials [10,14]. In a lymphopenic condition, the circu-
lating levels of IL-7 increase, thereby promoting lymphocyte 
development in the thymus and maintaining the homeosta-
sis of peripheral naive and memory T cells [15].
However, few studies have evaluated the effect of IL-7 
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on radiation-induced lymphopenia, which is characterized 
by the rapid depletion of lymphocytes during radiotherapy. 
Therefore, we aimed to identify the role of IL-7 in radiation-
induced lymphopenia and to determine the risk factors and 
prognostic significance of radiation-induced lymphopenia 




We performed a post-hoc analysis in a prospective cohort 
of patients with hepatocellular carcinoma who were treated 
with radiotherapy between July 2016 and October 2018. The 
cohort was originally established to determine serum bio-
markers for predicting treatment outcomes after radiother-
apy in patients with locally advanced hepatocellular carci-
noma.
The eligibility criteria were as follows: (1) unresectable pri-
mary hepatocellular carcinoma treated with radiotherapy, 
(2) age > 20 years, (3) Eastern Cooperative Oncology Group 
performance status of 0-2, (4) Child-Pugh class A/B, (5) 
normal liver volume > 1,000 cm3, (6) distance between the 
liver and organs at risk ≥ 0.5 cm, (7) adequate liver function 
(aspartate aminotransferase/alanine aminotransferase < 5 
times the upper limit of normal, total bilirubin < 3.0 mg/dL, 
albumin > 2.5 g/dL, and normal prothrombin time/partial 
thromboplastin time), (8) adequate renal function (creatinine 
< 1.8 mg/dL or creatinine clearance rate > 50 mL/min), and 
(9) bone marrow reserve (absolute neutrophil count ≥ 1,500/
mm3, platelet count ≥ 50,000/mm3; and hemoglobin level 
> 9 g/dL). Patients who received stereotactic body radiother-
apy or previous radiotherapy to the upper abdomen were 
excluded. Ninety-nine patients were enrolled. One patient 
who had received radiotherapy to the head and neck for a 
separate malignancy was excluded, because previous radio-
therapy may have affected the total lymphocyte count. In 
total, 98 patients were analyzed.
Conventional radiotherapy was administered to all pati-
ents, most of whom received the same dose/fractionation. 
Ninety-one patients (92.9%) received 100 Gy in 25 fractions to 
the gross tumor volume and 60 Gy in 25 fractions to the plan-
ning target volume using the simultaneous integrated boost 
technique. Sixty-six patients received combination therapy: 
concurrent hepatic arterial infusion chemotherapy (500 mg/
m2/day of 5-fluorouracil) during the first and fifth week of 
radiotherapy (n=63) [16] or daily tegafur-uracil (n=3). The 
remaining 33 patients received radiotherapy only.
2. Assessment of total lymphocyte count
Peripheral blood counts were measured weekly during 
radiotherapy and then every 1-3 months after radiothera-
py for 1 year. Total lymphocyte count data were classified 
according to the number of months from the initiation of 
radiotherapy. Lymphopenia was graded using the Com-
mon Terminology Criteria for Adverse Events ver. 4.0 [17]. 
A total lymphocyte count from the lower limit of normal to 
800 cells/μL was considered as grade 1; 500-800 cells/μL, 
grade 2; 200-500 cells/μL, grade 3; and < 200 cells/μL, grade 
4. Acute severe lymphopenia (ASL) was defined as a total 
lymphocyte count of < 200 cells/μL during radiotherapy (i.e., 
grade 4 lymphopenia).
3. IL-7 cytokine assays
Blood samples (5-10 mL) were collected in vacutainer 
tubes (BD, Franklin Lakes, NJ) containing ethylenediami-
netetraacetic acid before and at the last day of radiotherapy. 
The blood samples were centrifuged at 3,000 rpm for 10 min-
utes at 4°C to separate the buffy coat and plasma. Additional 
centrifugation for 10 minutes was performed to obtain cell-
free plasma. The plasma aliquots were collected within 1-2 
hours of blood sampling and frozen at –80°C until further 
processing. Plasma IL-7 concentrations were determined 
using a magnetic bead-based 6-plex immunoassay (custom-
ized Procartaplex, Thermo Scientific, Waltham, MA). Briefly, 
standards at different concentrations and patient plasma 
samples were mixed with antibody-linked polystyrene 
beads in 96-well filter-bottom plates and incubated at room 
temperature for 2 hours on an orbital shaker at 500 rpm. The 
plate was inserted into a magnetic plate washer and washed 
twice, followed by incubation with a biotinylated detection 
antibody mixture for 30 minutes at room temperature on an 
orbital shaker at 500 rpm. The samples were washed twice 
and resuspended in streptavidin-phycoerythrin. After incu-
bation for 30 minutes at room temperature, two additional 
washes were performed, and the samples were resuspended 
in reading buffer. Each sample was measured in duplicate 
along with the standards (seven-point dilutions) and buffer 
control. Plates were read on the Luminex MAGPIX System 
(Merck Millipore, Burlington, MA) for quantitative analysis. 
The median fluorescence intensity of the analytes was detect-
ed using the flow-based MAGPIX System (Merck Millipore). 
Cytokine concentrations were calculated using Luminex 
xPONENT 4.2 software. A five-parameter model was used to 
calculate the final concentrations via interpolation.
4. Statistical analysis
Two-sided unpaired or paired t tests were used for statisti-
cal analysis. Survival rates were calculated from the time of 
the initiation of radiotherapy using the Kaplan-Meier meth-
od and compared using the log-rank test. Cox regression 
and binary logistic regression modeling were performed to 
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identify predictors of overall survival and ASL development, 
respectively; backward stepwise selection of variables was 
performed. The predictive value of pre-radiotherapy IL-7 
levels for ASL development was assessed using receiver 
operating characteristic curve analysis. The optimal cut-
off value was determined using Youden’s index. Statistical 
analyses were performed using SPSS ver. 25.0 (IBM Corp., 
Armonk, NY) and Prism 7 (GraphPad Software, La Jolla, 




The patient, tumor, and treatment characteristics are sum-
marized in Table 1. The median tumor size was 6.5 cm (range, 
1.3 to 21.0 cm), and the median planning target volume 
was 594 cm3 (range, 37 to 5,156 cm3). Most patients (87.8%) 
had Child-Pugh class A disease. Approximately half of the 
patients had Barcelona Clinic Liver Cancer stage C disease. 
The majority of patients had hepatitis B virus infection 
(73.5%). No inflammatory or autoimmune diseases other 
than hepatitis were noted.
2. Changes in total lymphocyte count over time
The mean total lymphocyte count decreased to 27% at 1 
month after the initiation of radiotherapy, recovered to 104% 
of the baseline level at 2 months, and then remained low at 
60%-70% of the initial level from 3-6 months (Fig. 1A). When 
compared to the mean baseline total lymphocyte count (1,122 
cells/μL), the mean total lymphocyte count was significantly 
reduced at 1 month after the initiation of radiotherapy (305 
cells/μL) and at 3 (787 cells/μL), 4 (775 cells/μL), 5 (686 
cells/μL), and 6 months (752 cells/μL) (Bonferroni-adjusted 
p < 0.001). The mean total lymphocyte count at 2 months 
was not significantly different from that at baseline. During 
radiotherapy, 41 of 98 patients (41.8%) developed ASL.
3. Effects of the development of and recovery from radia-
tion-induced lymphopenia on survival outcomes
The median follow-up was 20.5 months (range, 2.8 to 
42.2 months). Patients with ASL had poorer overall survival 
(2-year overall survival rate, 30.3% vs. 50.2%; median, 12.0 
months vs. 25.3 months; p=0.001) and progression-free sur-
vival (2-year progression-free survival rate, 8.1% vs. 20.4%; 
median, 6.4 months vs. 10.2 months; p=0.066) than those 
without. Among patients with ASL, those who recovered 
(total lymphocyte count > 1,000 cells/μL at 2 months, n=20) 
had significantly longer overall survival than those who did 
not (n=21) (2-year overall survival rate, 41.7% vs. 19.0%; 
median, 21.8 months vs. 10.3 months; p=0.042). Patients who 
recovered from ASL had an overall survival similar to that 
of those who initially had no ASL (median, 21.8 months vs. 
25.3 months; p=0.158), while patients who did not recover 
had the poorest overall survival (median, 10.3 months) (Fig. 
1B-E).
Table 1.  Patient characteristics
Characteristic Value (n=98)
Age (yr) 61 (33-80)
Sex 
    Male 78 (79.6)
    Female 20 (20.4)
Viral type 
    B-viral 72 (73.5)
    C-viral 5 (5.1)
    Non-B/Non-C viral 21 (21.4)
Child-Pugh class 
    A 86 (87.8)
    B 12 (12.2)
Liver cirrhosis 
    No 53 (54.1)
    Yes 45 (45.9)
Tumor size (cm) 6.5 (1.3-21.0)
No. of tumors 
    One 43 (43.9)
    Multiple 55 (56.1)
UICC stage 
    Stage II 27 (27.6)
    Stage III 31 (31.6)
    Stage IV 40 (40.8)
BCLC stage 
    Stage A 24 (24.5)
    Stage B 26 (26.5)
    Stage C 48 (49.0)
Portal vein thrombosis 
    No 52 (53.1)
    Yes 46 (46.9)
AFP (ng/mL) 64.4 (1.7-268,408)
PIVKA-II (mAU/mL) 1,616 (15-75,000)
Previous treatment 
    No 51 (52.0)
    Yes 47 (48.0)
Combined treatment  
    Concurrent chemoradiotherapy 66 (67.3)
    Radiotherapy alone 32 (32.7)
Radiation dose (Gy) 100 (60-100)
Planning target volume size (cm3) 594 (37-5,156)
Values are presented as median (range) or number (%). AFP, 
α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; PIVKA-II, 
protein induced by vitamin K absence-II; UICC, Union for Inter-
national Cancer Control.
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In multivariable analysis, Child–Pugh class B disease 
(hazard ratio [HR], 2.27, 95% confidence interval [CI], 1.15 
to 4.49; p=0.018), the Union for International Cancer Control 
stage III/IV (HR, 1.78; 95% CI, 1.27 to 2.50; p=0.001), and ASL 
development (HR, 2.03; 95% CI, 1.24 to 3.31; p=0.005) were 
significant predictors of poor overall survival (Table 2).
Fig. 1.  (A) Changes in the mean (standard deviation) total lymphocyte count (TLC) over time after the initiation of radiotherapy (RT). (B) 
Overall survival according to the presence of acute severe lymphopenia (ASL). (C) Progression-free survival according to the presence of 































































































































ASL & no recovery
No. at risk
ASL & recovery









































ASL & no recovery
No. at risk
No ASL
ASL & recovery 
ASL & no recoveryp=0.042
Hwa Kyung Byun, Role of IL-7 in Radiation-Induced Lymphopenia
VOLUME 53 NUMBER 4 OCTOBER 2021     965
4. Effects of IL-7 on the development of and recovery from 
radiation-induced lymphopenia
The median pre- and post-radiotherapy IL-7 levels for all 
patients were 2.22 pg/mL (range, 0.24 to 9.79 pg/mL) and 
2.20 pg/mL (range, 0.20 to 7.33 pg/mL), respectively. Pre-
radiotherapy IL-7 levels were significantly lower in patients 
who developed ASL than in those who did not (mean, 2.07 
pg/mL vs. 3.01 pg/mL; p=0.010) (Fig. 2A). Pre-radiotherapy 
IL-7 levels were significantly positively correlated with the 
total lymphocyte count nadir during radiotherapy (Fig. 2C).
Differences in IL-7 levels before and after radiotherapy 
(post-radiotherapy minus pre-radiotherapy IL-7 levels 
[ΔIL-7]) were significantly higher in patients with ASL than 
in those without (mean, 0.48 pg/mL vs. –0.66 pg/mL; p < 
0.001). The mean IL-7 level was significantly elevated after 
radiotherapy in patients with ASL (pre-radiotherapy vs. 
post-radiotherapy IL-7 levels, 2.07 pg/mL vs. 2.55 pg/mL; 
p=0.029), whereas it was significantly reduced in patients 
without ASL (3.01 pg/mL vs. 2.35 pg/mL, p=0.005) (Fig. 2B). 
The ΔIL-7 was significantly negatively correlated with the 
total lymphocyte count nadir during radiotherapy (Fig. 2D). 
The total lymphocyte count at 2 months after the initiation 
of radiotherapy was significantly positively correlated with 
post-radiotherapy IL-7 levels (Fig. 2E). 
In multivariable analysis, grade ≥ 1 lymphopenia at base-
line (HR, 29.81; 95% CI, 6.54 to 135.82; p < 0.001) and a large 
planning target volume (per 100 cm3 increase; HR, 1.23; 95% 
CI, 1.11 to 1.36; p < 0.001) were significantly associated with 
an increase in the incidence of ASL, while elevated pre- 
radiotherapy IL-7 levels were significantly associated with a 
decrease in the incidence of ASL (per 1 pg/mL increase; HR, 
0.39; 95% CI, 0.22 to 0.69; p=0.001). Hepatitis B virus infec-
tion showed marginal significance (HR, 7.26; 95% CI, 0.98 to 
53.79; p=0.052) (Table 3). In a separate multivariable analysis 
including the mean liver dose instead of the planning target 
volume, pre-radiotherapy IL-7 levels were an independent 
predictor of ASL development as well, along with grade ≥ 1 
lymphopenia at baseline and mean liver dose (S1 Table).
Since pre-radiotherapy IL-7 levels were an independent 
predictor of ASL development, we classified patients into 
high and low pre-radiotherapy IL-7 groups using a cut-off 
value of 2.495 pg/mL (Table 4). The characteristics, except for 
Child-Pugh class and planning target volume, did not dif-
fer significantly between the groups. Twelve of 45 patients 
(26.7%) in the high pre-radiotherapy IL-7 group and 29 of 
53 patients (54.7%) in the low pre-radiotherapy IL-7 group 
developed ASL (p=0.005).
The toxicity profile is shown in S2 Table. Neither pre- nor 
post-radiotherapy IL-7 levels differed significantly according 
to the presence of grade ≥ 2 gastrointestinal or liver toxicity.
 
Table 2.  Analysis of factors associated with overall survival
Variable
                           Univariate analysis                          Multivariate analysis
 HR (95% CI) p-value HR (95% CI) p-value
Age > 60 yr (vs. ≤ 60 yr) 0.63 (0.38-1.02) 0.059 - -
Female (vs. male) 0.86 (0.47-1.59) 0.636 - -
Hepatitis viral infection (vs. no) 1.01 (0.57-1.81) 0.966 - -
Multiple tumors (vs. single tumor) 2.16 (1.30-3.61) 0.003 - -
Liver cirrhosis (vs. no) 1.59 (0.98-2.58) 0.061 1.51 (0.93-2.47) 0.097
Child-Pugh class B (vs. A) 2.74 (1.41-5.31) 0.003 2.27 (1.15-4.49) 0.018
PVTT (vs. no) 1.72 (1.06-2.80) 0.029 - -
Previous treatment (vs. no) 0.75 (0.46-1.23) 0.249 - -
UICC stage III/IV (vs. I/II) 2.24 (1.20-4.20) 0.012 1.78 (1.27-2.50) 0.001
AFP (per 1 ng/mL increase) 1.00 (1.00-1.00) 0.026 - -
PIVKA-II (per 1 mAU/mL increase) 1.00 (1.00-1.00) 0.108 - -
Baseline lymphopenia (≤ 1,000 cells/μL; vs. no) 1.55 (0.95-2.51) 0.079 - -
Combined therapy (vs. radiotherapy alone) 2.25 (1.24-4.08) 0.007 - -
Total radiation dose (per 1 Gy increase) 1.01 (0.97-1.05) 0.788 - -
Pre-radiotherapy IL-7 (per 1 pg/mL increase) 1.00 (0.87-1.14) 0.975 - -
Post-radiotherapy IL-7 (per 1 pg/mL increase) 1.14 (0.96-1.35) 0.146 - -
Acute severe lymphopeniaa) (vs. no) 2.16 (1.33-3.51) 0.002 2.03 (1.24-3.31) 0.005
AFP, α-fetoprotein; CI, confidence interval; HR, hazard ratio; IL-7, interleukin-7; PIVKA-II, protein induced by vitamin K absence-II; PVTT, 
portal vein tumor thrombosis; UICC, Union for International Cancer Control. a)Acute severe lymphopenia was defined as a total lympho-
cyte count of < 200 cells/μL during radiotherapy (i.e., grade 4 lymphopenia). 
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Discussion
We confirmed the previous findings that peripheral local 
radiotherapy can induce systemic lymphopenia and that 
radiation-induced lymphopenia can have detrimental effects 
on survival outcomes [1-6]. Most studies reported these 
findings using retrospective data. Our findings are mean-
ingful because we obtained these results from a prospective 
cohort using a well-controlled blood test protocol and treat-
ment schedule. We also suggest the role of IL-7 in radiation- 
induced lymphopenia based on our findings. 
Emerging evidence suggests that radiation-induced lym-
phopenia has detrimental effects on the pathological respons-
es and survival of patients with various types of cancer [1-6]. 
Since preserving the optimal lymphocyte count in the blood 
may be essential in achieving successful treatment outcomes, 
novel strategies to prevent and reverse radiation-induced 
lymphopenia are urgently needed. To develop these strate-
gies, risk factors for radiation-induced lymphopenia need 
to be identified first. Previous studies have reported various 
radiotherapy-related risk factors, such as photon- vs. proton-
based radiotherapy [18], brain volume receiving 25 Gy [19], 
and conventional vs. stereotactic body radiotherapy [4,20]. A 
previous mathematical model demonstrated that the chance 
of delivering radiation to circulating blood increases as the 
planning target volume and the number of fractions increase 
[21]. In a previous study, we retrospectively evaluated 920 
patients with hepatocellular carcinoma who received radio-
therapy. We found that a low baseline total lymphocyte 
count, large planning target volume, and multiple fractiona-
tions were risk factors for radiation-induced lymphopenia 
[5]. In the current study involving an independent prospec-
tive cohort, a low baseline total lymphocyte count and large 
planning target volume were also risk factors for ASL deve-
lopment, confirming our previous findings. Since most 
patients received the same dose fractionation regimen, we 
were unable to determine the influence of dose fractionation.
In addition to previously known predictors of radiation-
induced lymphopenia, this study also identified an associa-
tion between serum IL-7 levels and radiation-induced lym-
phopenia. To our knowledge, this study is one of the first to 
identify such an association. IL-7 induces lymphocyte prolif-
eration and differentiation by activating various molecular 
pathways [15]. Changes in IL-7 levels precede changes in 
lymphocyte counts. Consistent with this, in our study, pre-
radiotherapy IL-7 levels were significantly positively corre-
lated with the total lymphocyte count nadir during radio-
therapy and were an independent predictor of a reduced risk 
of ASL development. Considering the clinical relevance, we 
focused on the analysis of pre-radiotherapy IL-7 levels.
When patients were divided according to pre-radiothera-
py IL-7 levels (Table 4), the high pre-radiotherapy IL-7 group 
had a significantly lower incidence of ASL, even though 
this group had a larger planning target volume. Consider-
Table 3.  Analysis of factors affecting the development of acute severe lymphopeniaa)
Variable
                           Univariate analysis                          Multivariate analysis
 OR (95% CI) p-value OR (95% CI) p-value
Age > 60 yr (vs. ≤ 60 yr) 0.33 (0.14-0.75) 0.009 - -
Female (vs. male) 0.91 (0.33-2.47) 0.852 - -
Hepatitis viral infection (vs. no infection) 1.22 (0.45-3.28) 0.695 7.26 (0.98-53.79) 0.052
Multiple tumors (vs. single tumor) 1.18 (0.53-2.66) 0.683 - -
Liver cirrhosis (vs. no) 2.42 (1.06-5.51) 0.035 - -
Child-Pugh class B (vs. A) 2.14 (0.63-7.3) 0.224 - -
PVTT (vs. no) 3.86 (1.65-9.01) 0.002 - -
Previous treatment (vs. no) 0.38 (0.16-0.87) 0.022 - -
UICC stage III/IV (vs. I/II) 2.63 (0.99-6.99) 0.053 - -
AFP (per 1 ng/mL increase) 1.00 (1.00-1.00) 0.159 - -
PIVKA-II (per 1 mAU/mL increase) 1.00 (1.00-1.00) 0.012 - -
Baseline lymphopenia (≤ 1,000 cells/μL; vs. no) 11.55 (4.37-30.52) < 0.001 29.81 (6.54-135.82) < 0.001
Combined therapy (vs. radiotherapy alone) 4.89 (1.78-13.44) 0.002 - -
Total radiation dose (per 1 Gy increase) 1.03 (0.96-1.12) 0.384 - -
Planning target volume size (per 100 cm3 increase) 1.08 (1.03-1.12) < 0.001 1.23 (1.11-1.36) < 0.001
Pre-radiotherapy IL-7 (per 1 pg/mL increase) 0.71 (0.54-0.94) 0.015 0.39 (0.22-0.69) 0.001
AFP, α-fetoprotein; CI, confidence interval; IL-7, interleukin-7; OR, odds ratio; PIVKA-II, protein induced by vitamin K absence-II; PVTT, 
portal vein tumor thrombosis; UICC, Union for International Cancer Control. a)Acute severe lymphopenia was defined as a total lympho-
cyte count of < 200 cells/μL during radiotherapy (i.e., grade 4 lymphopenia).
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ing planning target volume as a risk factor for ASL devel-
opment, as shown in other studies [2,5,21], as well as in the 
current study, the high pre-radiotherapy IL-7 group was 
expected to have a higher incidence of ASL. However, it did 
not. Therefore, we assumed that although a large planning 
target volume was associated with an increased risk of ASL 
development, such a risk may be mitigated by a high pre-
radiotherapy IL-7 level.
Furthermore, we observed a complementary feedback 
response of IL-7 on changes in total lymphocyte count dur-
Table 4.  Patient characteristics according to pre-radiotherapy IL-7 levels
Variable 
Low pre-radiotherapy IL-7 High pre-radiotherapy IL-7  
p-value
 (≤ 2.495 pg/mL) (n=53) (> 2.495 pg/mL) (n=45) 
Age (yr) 60±10 62±10 0.489(
Sex   
    Male 39 (73.6) 39 (86.7) 0.109
    Female 14 (26.4) 6 (13.3) 
Viral type   
    B-viral 42 (79.2) 30 (66.7) 0.252
    C-viral 3 (5.7) 2 (4.4) 
    Non-B/Non-C viral 8 (15.1) 13 (28.9) 
Child-Pugh class   
    A 50 (94.3) 36 (80.0) 0.031
    B 3 (5.7) 9 (20.0) 
Liver cirrhosis   
    No 27 (50.9) 26 (57.8) 0.499
    Yes 26 (49.1) 19 (42.2) 
Tumor size (cm) 7.2±4.9 9.1±5.7 0.082
No. of tumors   
    One 26 (49.1) 17 (37.8) 0.262
    Multiple 27 (50.9) 28 (62.2) 
UICC stage   
    Stage II 17 (32.1) 10 (22.2) 0.304
    Stage III 18 (34.0) 13 (28.9) 
    Stage IV 18 (34.0) 22 (48.9) 
BCLC stage   
    Stage A 15 (28.3) 9 (20.0) 0.511
    Stage B 12 (22.6) 14 (31.1) 
    Stage C 26 (49.1) 22 (48.9) 
Portal vein thrombosis   
    No 28 (52.8) 24 (53.3) 0.960
    Yes 25 (47.2) 21 (46.7) 
AFP (ng/mL) 12,311±41,238 8,472±26,004 0.591
PIVKA-II (mAU/mL) 8,927±19,944 10,497±18,939 0.692
Previous treatment   
    No 28 (52.8) 23 (51.1) 0.865
    Yes 25 (47.2) 22 (48.9) 
Combined treatment   
    Concurrent chemoradiotherapy 15 (28.3) 17 (37.8) 0.319
    Radiotherapy alone 38 (71.7) 28 (62.2) 
Highest prescribed radiation dose (Gy) 98±7 99±6 0.272
Planning target volume (cm3) 962±1,140 1,441±1,200 0.045
Mean liver dose (Gy) 38.6±19.9 46.5±22.6 0.072
Values are presented as mean±SD or number (%). AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; IL-7, interleukin-7; PIVKA-II, 
protein induced by vitamin K absence-II; SD, standard deviation; UICC, Union for International Cancer Control.
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ing radiotherapy. The ΔIL-7 was negatively associated with 
total lymphocyte count during radiotherapy. The ΔIL-7 had 
a positive value among patients with ASL and a negative 
value among those without. Changes in serum IL-7 levels 
are known to reflect changes in the population of T-cells that 
consume cytokines [22]. Under lymphopenic conditions, 
T-cells encounter abundant IL-7, leading to homeostatic 
proliferation [23,24]. In contrast, when T-cells over prolifer-
ate, and patients become non-lymphopenic, IL-7 levels are 
reduced due to over consumption, leading to T cell death. 
Our findings are contrary to those of Ellsworth et al. [25]. 
In their study, patients with high-grade glioma treated with 
concurrent chemoradiotherapy showed lymphocyte deple-
tion, but no increase in IL-7 levels. However, in addition to 
the small number of patients (n=11) in that study, IL-7 levels 
were not stratified according to the presence of lymphope-
nia, unlike in the current study. These discrepancies may 
have led to the different interpretations about the role of IL-7 
in radiation-induced lymphopenia.
Our data showed that ASL was an independent predic-
tor of poor overall survival, confirming previous findings 
[1-6]. There were no direct associations between pre- or post-
radiotherapy IL-7 levels and overall survival. Therefore, 
we assumed that high IL-7 levels may indirectly influence 
survival by means of total lymphocyte count preservation. 
The administration of exogenous IL-7 before radiotherapy 
can be a good option to prevent a decline in total lympho-
cyte count during radiotherapy, particularly in patients with 
a high risk of ASL due to a large planning target volume, 
multiple fractionations, or a low baseline total lymphocyte 
count. The effect of exogenous IL-7 on increasing the num-
ber of T lymphocytes has been demonstrated in earlier stud-
ies of human immunodeficiency virus-infected patients and 
patients with melanoma or sarcoma [13,26]. Currently, a clini-
cal study is being conducted to assess the ability of exogenous 
IL-7 to restore the total lymphocyte count after radiotherapy 
[27]. The finding that elevated IL-7 levels after radiotherapy 
were associated with lymphocyte recovery suggests that IL-7 
can also be administered after radiotherapy for lymphocyte 
recovery; this is important because, according to our results, 
ASL recovery mitigated poor survival outcomes. A retro-
spective study of 167 patients with solid tumors treated with 
immune checkpoint inhibitors also showed that rapid 
recovery of the total lymphocyte count is associated with 
improved outcomes [28]. In some patients, IL-7 is not 
secreted despite the low total lymphocyte count during radi-
otherapy, as can be observed in the lower left part of Fig. 2D. 
This may be attributed to the lack of feedback mechanisms. 
Accordingly, those patients may be candidates who may ben-
efit from exogenous IL-7 administration after radiotherapy.
A limitation of our study is that the type of tumor was con-
fined to hepatocellular carcinoma. However, compared with 
other types of tumors, hepatocellular carcinoma has a unique 
feature with regard to radiotherapy-related lymphopenia in 
that the liver harbors a very rich blood supply and the tumor 
itself is hypervascular, leading to a greater amount of blood 
being exposed to radiation, which can maximize the radia-
tion effect and cause lymphopenia [5]. Another limitation, 
considering the dynamic changes in IL-7 levels, is that only 
two samples were obtained. Further studies are needed to 
understand the relationship between the dynamic changes 
in IL-7 levels and radiation-induced lymphopenia. Finally, 
immune reactions during radiotherapy may be related to dif-
ferent types of cytokines and immune cells. However, in this 
study, we only focused on IL-7 levels and total lymphocyte 
counts [29]. Our results should be interpreted with caution, 
and the relationship between various cytokines or immune 
cells and radiation-induced lymphopenia should be addre-
ssed in future studies.
In conclusion, IL-7 levels are associated with the preven-
tion of and recovery from radiation-induced lymphopenia. 
Radiation-induced lymphopenia and no recovery from it 
were associated with poor survival. High IL-7 levels may 
indirectly influence survival by means of total lympho-
cyte count preservation. Therefore, to overcome radiation- 
induced lymphopenia and to enhance the therapeutic effect 
of radiotherapy, a novel strategy using the cytokine IL-7 (e.g., 
the administration of exogenous IL-7) may be considered.
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